Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.

Also called NCT01643031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01643031
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Israel (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01643031. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
Acronym
MATTIS-D
Condition
Diabetes Mellitus
Condition
Coronary Disease
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Continued clopidogrel
Lead sponsor
Rabin Medical Center (class: other)
Collaborator
Tel Aviv Medical Center (class: other)
Collaborator
Sheba Medical Center (class: other government)
Collaborator
Meir Medical Center (class: other)
Collaborator
Rambam Health Care Campus (class: other)

Record details

Record id
cardio:ct-nct01643031
Content hash
7c5bb03b4f27603c40117dfcc51f4ea9b6c88786fa6d9d5acf32dd54ebf3bdab